9.25
+0.26(+2.89%)
Currency In USD
| Previous Close | 8.99 |
| Open | 8.96 |
| Day High | 9.3 |
| Day Low | 8.94 |
| 52-Week High | 12.61 |
| 52-Week Low | 5.37 |
| Volume | 905,192 |
| Average Volume | 1.66M |
| Market Cap | 1.02B |
| PE | -3.73 |
| EPS | -2.48 |
| Moving Average 50 Days | 8.53 |
| Moving Average 200 Days | 9.17 |
| Change | 0.26 |
If you invested $1000 in Cogent Biosciences, Inc. (COGT) since IPO date, it would be worth $208.15 as of February 05, 2025 at a share price of $9.25. Whereas If you bought $1000 worth of Cogent Biosciences, Inc. (COGT) shares 5 years ago, it would be worth $2,854.94 as of February 05, 2025 at a share price of $9.25.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cogent Biosciences to Participate in the Guggenheim Biotech Conference
GlobeNewswire Inc.
Jan 30, 2025 1:00 PM GMT
WALTHAM, Mass. and BOULDER, Colo., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in a
Cogent Biosciences Announces Planned 2025 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics
GlobeNewswire Inc.
Jan 13, 2025 1:00 PM GMT
• Plan to report top-line results from registration-directed SUMMIT trial in NonAdvSM patients in July 2025 • Plan to report top-line results from pivotal PEAK Phase 3 trial in 2nd-line GIST patients by end of 2025 • Plan to report top-line res
Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 08, 2025 1:00 PM GMT
WALTHAM, Mass. and BOULDER, Colo., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, P